Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Substance (Drug) Abuse-Pipeline Review, H1 2015

Substance (Drug) Abuse-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Substance (Drug) Abuse-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Substance (Drug) Abuse-Pipeline Review, H1 2015', provides an overview of the Substance (Drug) Abuse's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Substance (Drug) Abuse and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Substance (Drug) Abuse products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Substance (Drug) Abuse

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Substance (Drug) Abuse pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Substance (Drug) Abuse Overview 7

Therapeutics Development 8

Pipeline Products for Substance (Drug) Abuse-Overview 8

Pipeline Products for Substance (Drug) Abuse-Comparative Analysis 9

Substance (Drug) Abuse-Therapeutics under Development by Companies 10

Substance (Drug) Abuse-Therapeutics under Investigation by Universities/Institutes 11

Substance (Drug) Abuse-Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Substance (Drug) Abuse-Products under Development by Companies 14

Substance (Drug) Abuse-Products under Investigation by Universities/Institutes 15

Substance (Drug) Abuse-Companies Involved in Therapeutics Development 16

Addex Therapeutics Ltd 16

Aelis Farma S.A.S. 17

Foresee Pharmaceuticals, LLC 18

Grunenthal GmbH 19

Indivior PLC 20

InterveXion Therapeutics LLC 21

P2D Bioscience 22

Zynerba Pharmaceuticals, Inc. 23

Substance (Drug) Abuse-Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

2E-2-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

ADX-71743-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

ADX-88178-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

AEF-0117-Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Ch-mAb7F9-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

dronabinol-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

Enzyme for Cocaine Addiction-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

FP-004-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

RBP-8000-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

RO-656570-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecule to Antagonize Dopamine D1, D2 and D3 Receptors for Cocaine Use Disorder-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse and Alcohol Addiction-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules to Inhibit CB1 Receptor for Cannabinoid Abuse and Drug Addiction-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Vaccine for Drug Abuse-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Vaccine for Methamphetamine Abuse-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

VU-0463841-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Substance (Drug) Abuse-Recent Pipeline Updates 53

Substance (Drug) Abuse-Dormant Projects 55

Substance (Drug) Abuse-Product Development Milestones 57

Featured News & Press Releases 57

Jan 29, 2015: InterveXion Therapeutics, a UAMS Startup, Receives $14.5 Million to Develop Drug Therapies for Methamphetamine Users 57

Jan 05, 2015: InterveXion Therapeutics Receives $5 Million To Support Production Of The Anti-Methamphetamine Monoclonal Antibody 58

Dec 20, 2012: Addex Scientists Discover And Characterize First Potent And Selective Small Molecule Negative Allosteric Modulator Targeting mGlu7 Receptor 59

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

List of Tables

Number of Products under Development for Substance (Drug) Abuse, H1 2015 8

Number of Products under Development for Substance (Drug) Abuse-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Development, H1 2015 13

Products under Development by Companies, H1 2015 14

Products under Investigation by Universities/Institutes, H1 2015 15

Substance (Drug) Abuse-Pipeline by Addex Therapeutics Ltd, H1 2015 16

Substance (Drug) Abuse-Pipeline by Aelis Farma S.A.S., H1 2015 17

Substance (Drug) Abuse-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 18

Substance (Drug) Abuse-Pipeline by Grunenthal GmbH, H1 2015 19

Substance (Drug) Abuse-Pipeline by Indivior PLC, H1 2015 20

Substance (Drug) Abuse-Pipeline by InterveXion Therapeutics LLC, H1 2015 21

Substance (Drug) Abuse-Pipeline by P2D Bioscience, H1 2015 22

Substance (Drug) Abuse-Pipeline by Zynerba Pharmaceuticals, Inc., H1 2015 23

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Stage and Target, H1 2015 26

Number of Products by Stage and Mechanism of Action, H1 2015 28

Number of Products by Stage and Route of Administration, H1 2015 30

Number of Products by Stage and Molecule Type, H1 2015 32

Substance (Drug) Abuse Therapeutics-Recent Pipeline Updates, H1 2015 53

Substance (Drug) Abuse-Dormant Projects, H1 2015 55

Substance (Drug) Abuse-Dormant Projects (Contd..1), H1 2015 56

List of Figures

Number of Products under Development for Substance (Drug) Abuse, H1 2015 8

Number of Products under Development for Substance (Drug) Abuse-Comparative Analysis, H1 2015 9

Number of Products under Development by Companies, H1 2015 10

Number of Products under Investigation by Universities/Institutes, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 12

Comparative Analysis by Early Stage Products, H1 2015 13

Assessment by Monotherapy Products, H1 2015 24

Number of Products by Top 10 Targets, H1 2015 25

Number of Products by Stage and Top 10 Targets, H1 2015 26

Number of Products by Top 10 Mechanism of Actions, H1 2015 27

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28

Number of Products by Top 10 Routes of Administration, H1 2015 29

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30

Number of Products by Top 10 Molecule Types, H1 2015 31

Number of Products by Stage and Top 10 Molecule Types, H1 2015 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Addex Therapeutics Ltd

Aelis Farma S.A.S.

Foresee Pharmaceuticals, LLC

Grunenthal GmbH

Indivior PLC

InterveXion Therapeutics LLC

P2D Bioscience

Zynerba Pharmaceuticals, Inc.

Substance (Drug) Abuse Therapeutic Products under Development, Key Players in Substance (Drug) Abuse Therapeutics, Substance (Drug) Abuse Pipeline Overview, Substance (Drug) Abuse Pipeline, Substance (Drug) Abuse Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com